Literature DB >> 16409121

Adeno-associated virus types 5 and 6 use distinct receptors for cell entry.

Michael P Seiler1, A Dusty Miller, Joseph Zabner, Christine L Halbert.   

Abstract

The transduction efficiency of adeno-associated virus (AAV) vectors in various somatic tissues is determined primarily by the viral capsid proteins. In contrast to vectors made with AAV type 2 capsids, those having type 5 or 6 capsids show high transduction rates in airway epithelial cells, in a range that should be sufficient for treating lung disease. Here we have compared the properties of vectors made with AAV5 or AAV6 capsid proteins to determine whether their receptor usage is similar, and found several differences between the viruses. First, an AAV6 vector did not hemagglutinate red blood cells, whereas an AAV5 vector did, and this property was sialic acid dependent. Second, AAV5 vector transduction required sialic acid in all cells tested, whereas AAV6 vector transduction was sialic acid dependent or independent, depending on the target cells tested. Third, levels of an AAV6 vector that interfered with entry of another AAV6 vector only poorly inhibited AAV5 vector transduction and vice versa. These results indicate that AAV5 and AAV6 vectors use distinct cellular receptors for cell entry. Although both AAV5 and AAV6 vectors exhibited high transduction rates in well-differentiated human airway epithelial cultures, they exhibited distinct cell-type transduction profiles in mouse lung that may reflect differences in receptor usage.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16409121     DOI: 10.1089/hum.2006.17.10

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  45 in total

1.  Directing integrin-linked endocytosis of recombinant AAV enhances productive FAK-dependent transduction.

Authors:  Paul M Kaminsky; Nicholas W Keiser; Ziying Yan; Diana C M Lei-Butters; John F Engelhardt
Journal:  Mol Ther       Date:  2012-01-10       Impact factor: 11.454

2.  Polarized AAVR expression determines infectivity by AAV gene therapy vectors.

Authors:  Bradley A Hamilton; Xiaopeng Li; Alejandro A Pezzulo; Mahmoud H Abou Alaiwa; Joseph Zabner
Journal:  Gene Ther       Date:  2019-04-08       Impact factor: 5.250

3.  The 37/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 9.

Authors:  Bassel Akache; Dirk Grimm; Kusum Pandey; Stephen R Yant; Hui Xu; Mark A Kay
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

4.  Alpha2,3 and alpha2,6 N-linked sialic acids facilitate efficient binding and transduction by adeno-associated virus types 1 and 6.

Authors:  Zhijian Wu; Edward Miller; Mavis Agbandje-McKenna; Richard Jude Samulski
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

5.  Identification and characterization of novel adeno-associated virus isolates in ATCC virus stocks.

Authors:  Michael Schmidt; Emmanuelle Grot; Peter Cervenka; Sandra Wainer; Charles Buck; John A Chiorini
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

Review 6.  Gene replacement therapies for duchenne muscular dystrophy using adeno-associated viral vectors.

Authors:  Jane T Seto; Julian N Ramos; Lindsey Muir; Jeffrey S Chamberlain; Guy L Odom
Journal:  Curr Gene Ther       Date:  2012-06       Impact factor: 4.391

7.  Tropism and toxicity of adeno-associated viral vector serotypes 1, 2, 5, 6, 7, 8, and 9 in rat neurons and glia in vitro.

Authors:  Douglas B Howard; Kathleen Powers; Yun Wang; Brandon K Harvey
Journal:  Virology       Date:  2007-11-26       Impact factor: 3.616

8.  Comparative biology of rAAV transduction in ferret, pig and human airway epithelia.

Authors:  X Liu; M Luo; C Guo; Z Yan; Y Wang; J F Engelhardt
Journal:  Gene Ther       Date:  2007-08-30       Impact factor: 5.250

Review 9.  Recombinant adeno-associated virus transduction and integration.

Authors:  Brian R Schultz; Jeffrey S Chamberlain
Journal:  Mol Ther       Date:  2008-05-20       Impact factor: 11.454

10.  Biodistribution and safety profile of recombinant adeno-associated virus serotype 6 vectors following intravenous delivery.

Authors:  Daniel Stone; Ying Liu; Zong-Yi Li; Robert Strauss; Eric E Finn; James M Allen; Jeffrey S Chamberlain; André Lieber
Journal:  J Virol       Date:  2008-05-14       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.